ArticleTherapeutic advances in medical oncology2022
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for
Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.Targeted oncology · 2026Review
- Efficacy and safety of chemotherapy alone or in combination with immune checkpoint inhibitors as the first-line treatment for patients with advanced HER2 -mutant non-small cell lung cancer: A multi-center retrospective study.Chinese medical journal · 2026Article
- Review
- Observational
- Optimization of First-Line Treatment Options in HER2-Altered Lung Adenocarcinoma: A Real-World Study.Cancer medicine · 2025Article
- HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the Top.Molecules (Basel, Switzerland) · 2025Review
- Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations.Journal of translational medicine · 2025Review
- Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.Journal of the Chinese Medical Association : JCMA · 2025Article
- First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis.Current oncology (Toronto, Ont.) · 2025Article
- Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature.Discover oncology · 2025Article
- Combination regimens as potential treatment of non-small-cell lung cancer patients with HER2 mutation in the real world: a multicenter study.Therapeutic advances in medical oncology · 2025Article
- Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboringFrontiers in immunology · 2025Article
- HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities.Frontiers in oncology · 2025Review
- Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.Cancers · 2024Review
- A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.Cancer medicine · 2024Article
- HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies.Cancers · 2024Review
- Dacomitinib exhibits promising activity against the rareHeliyon · 2024Article
- Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.European journal of clinical pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere have been no comprehensive large-scale studies that have evaluated the benefits of chemotherapy-based regimens in addressing
methods
resultsA total of 293 patients were screened, with an identification of
conclusionChemotherapy plus angiogenesis inhibitors may yield a greater survival benefit than chemotherapy alone in a first-line setting for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.